Innoscripta SE 2025 Results Boost Shares Amid Insider Moves – Market Reacts
Innoscripta SE’s 2025 results show a 69 % EBIT margin and a sharp share rally, yet executive transactions raise governance questions for investors.
3 minutes to read
Innoscripta SE
Innoscripta SE: Leading the Charge in Cloud-Based R&D Compliance Software
Innoscripta SE is a leading provider of cloud-based compliance software for research and development, offering innovative solutions that streamline the R&D process and ensure compliance with funding requirements.
3 minutes to read
Innoscripta SE Founders Step In to Support Slumping Share Price After IPO
Innoscripta SE, a company listed on the Frankfurt Stock Exchange, is experiencing a challenging period following its IPO, with its share price declining from a 52-week high of 120 EUR to 85.6 EUR, prompting founders to intervene with selective share…
2 minutes to read
Innoscripta SE Founders to Bolster Share Price with Strategic Purchases Amid Market Activity
The founders of Innoscripta SE plan to purchase up to €12 million in shares to support the company’s stock price, which has hit a 52-week low.
3 minutes to read
Innoscripta SE Poised for Financial Upswing with Proposed R&D Tax Incentive Changes
Innoscripta SE is poised for a potential revenue boost as the German government’s draft bill proposes changes to the R&D tax incentive scheme, which could significantly increase funding and revenue for the biotech company.
3 minutes to read